The Pakistan–China B2B Investment Conference on Pharmaceuticals, Biotechnology and Healthcare concluded in Islamabad with participating companies signing more than 120 memorandums of understanding, joint ventures and commercial agreements worth over $1.7 billion. The agreements cover pharmaceuticals, biotechnology, vaccines, biologics, active pharmaceutical ingredients, medical devices, clinical research and Traditional Chinese Medicine. The two-day conference was held in Islamabad on July 16–17 and brought together government institutions, regulators and private-sector representatives from both countries. Officials said follow-up work would begin to convert the signed understandings into binding contracts, factories and manufacturing plants, supporting technology transfer, local production and long-term industrial cooperation between Pakistan and China.
